Pharmacovigilance Risk Assessment Committee of European Medicines Agency and FDA investigating whether popular weight loss shots linked to increased risk of suicidal thoughts
The European Medicines Agency (EMA) has asked some licence holders of GLP-1 receptor agonists for evidence into associations with suicidal ideation and self-harm as part of a review. These drugs include Ozempic (semaglutide), Saxenda (liraglutide), and Wegovy (semaglutide) and are used to treat type 2 diabetes and in weight management.
The review was triggered by the Icelandic Medicines Agency in July after reports of suicidal thoughts and self-injury in people using liraglutide and semaglutide. The authorities have so far retrieved and analysed about 150 reports of possible cases of self-injury and suicidal thoughts.
The EMA’s …
The EU s drug watchdog will request more data from makers of a class of diabetes and weight-loss drugs including Ozempic and Wegovy to further investigate suicidal thoughts in some patients taking them.